WallStreetZenWallStreetZen

NASDAQ: EGRX
Eagle Pharmaceuticals Inc Earnings & Revenue

EGRX past earnings growth

How has EGRX's earnings growth performed historically?
Company
-49.73%
Industry
11.8%
Market
111.38%
EGRX's earnings have grown slower... subscribe to Premium to read more.
Earnings Growth vs Industry Performance
EGRX's earnings have grown slower... subscribe to Premium to read more.
Earnings Growth vs Market Performance
EGRX's earnings growth is slowing... subscribe to Premium to read more.
Accelerating Earnings Growth Performance

EGRX past revenue growth

How has EGRX's revenue growth performed historically?
Company
-5.38%
Industry
9.72%
Market
17.84%
EGRX's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
EGRX's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Market Performance
EGRX's revenue growth is slowing... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

EGRX earnings and revenue history

Current Revenue
$257.6M
Current Earnings
$11.9M
Current Profit Margin
4.6%

EGRX Return on Equity

Current Company
5%
Current Industry
11.8%
Current Market
-0.3%
EGRX's Return on Equity (5%)... subscribe to Premium to read more.
High Return on Equity Performance

Be the first to know when EGRX announces earnings.

EGRX Return on Assets

Current Company
3%
Current Industry
3.7%
EGRX is generating higher Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

EGRX Return on Capital Employed

Current Company
11.08%
Current Industry
6.8%
EGRX has gotten more efficient... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

EGRX vs Pharmaceutical Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
EGRX$257.55M$57.18M$11.95M+3.61%-14.47%
DERM$79.89M-$5.69M-$12.35M+16.03%N/A
RGC$0.00-$5.10M-$5.87MN/AN/A
IXHL$0.00N/A-$17.42M-100.00%N/A
SCYX$140.14M$70.89M$67.04M+252.64%N/A

EGRX earnings dates

Next earnings date
May 7, 2024

Eagle Pharmaceuticals Earnings & Revenue FAQ

What were EGRX's earnings last quarter?

On Invalid Date, Eagle Pharmaceuticals (NASDAQ: EGRX) reported Q2 2023 earnings per share (EPS) of $0.39, up 152.7% year over year. Total Eagle Pharmaceuticals earnings for the quarter were $5.16 million. In the same quarter last year, Eagle Pharmaceuticals's earnings per share (EPS) was -$0.74.

If you're new to stock investing, here's how to buy Eagle Pharmaceuticals stock.

What was EGRX's earnings growth in the past year?

As of Q1 2024, Eagle Pharmaceuticals's earnings has grown -49.73% year over year. This is 61.53 percentage points lower than the US Drug Manufacturers - Specialty & Generic industry earnings growth rate of 11.8%. Eagle Pharmaceuticals's earnings in the past year totalled $11.95 million.

What is EGRX's earnings date?

Eagle Pharmaceuticals's earnings date is Invalid Date. Add EGRX to your watchlist to be reminded of EGRX's next earnings announcement.

What was EGRX's revenue last quarter?

On Invalid Date, Eagle Pharmaceuticals (NASDAQ: EGRX) reported Q2 2023 revenue of $64.65 million up 12.8% year over year. In the same quarter last year, Eagle Pharmaceuticals's revenue was $74.14 million.

What was EGRX's revenue growth in the past year?

As of Q1 2024, Eagle Pharmaceuticals's revenue has grown -5.38% year over year. This is 15.09 percentage points lower than the US Drug Manufacturers - Specialty & Generic industry revenue growth rate of 9.72%. Eagle Pharmaceuticals's revenue in the past year totalled $257.55 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.